Direct-to-Consumer Genomics Reinvents Itself
By Malorye Allison,
Nature
| 11. 08. 2012
By putting its foot in the door at the FDA, can 23andMe reinvigorate direct-to-consumer genomics? Malorye Allison investigates.
In July, 23andMe filed for US Food and Drug Administration (FDA) clearance for 7 of its 200-plus genetics tests, the first 510(k) submissions from a direct-to-consumer (DTC) genetics business. The filing is considered de novo because there is no preexisting standard (“predicate device”), the usual benchmark used by the FDA to evaluate devices for premarket approval. Although individual tests cover some of the same genes, nothing on this scale has a 510(k) approval.
The filings were a surprise to many. In 2010, the FDA made it clear through a set of letters to the industry that it felt such tests needed regulation, yet the agency has done little publicly to clarify what the approval pathway might look like. Furthermore, the value of the information to consumers in these tests remains somewhat controversial. The American College of Obstetricians and Gynecologists, for one, believes that “there remains a paucity of evidence that more than a few of these SNPs [single-nucleotide polymorphisms], either alone or...
Related Articles
It’s been a busy couple of months in biopolitics, with developments in the US, UK, China, Japan, and implicitly on Mars. Time for a brief roundup.
• • •
Bioethics needs an update
The National Research Act is now 50 years old. It was signed into law on July 12, 1974, as a direct response to publicity about the 1932 “Tuskegee Study of Untreated Syphilis in the Negro Male.” The Hastings Bioethics Forum celebrated its anniversary with an...
Image courtesy National Human Genome Research Institute
The U.S. Food and Drug Administration (FDA) is supposed to encourage effective medical advances while also ensuring that patients and research subjects are protected. This dual mandate demands tricky judgment calls that are made more difficult by outside pressures of several kinds, political, judicial, and especially commercial. This April story at Bloomberg examines one deeply troubling pattern of regulatory capture:
Americans Are Paying Billions to Take Drugs That Don’t Work
Companies are increasingly...
By Elizabeth Chuck, NBC News | 07.09.2024
A Netflix docuseries has put a spotlight on the unregulated world of sperm donation, particularly the lack of stopgap measures that might prevent donors who have been banned by one country from simply going elsewhere to donate more.
Released earlier...
By Amanda Becker and Shefali Luthra, The 19th | 07.08.2024
Image by Duke University Archives from Flickr
Republicans have adopted a slate of policy positions ahead of next week’s convention that does not call for a federal legislative abortion ban, but opens the door to establishing fetal personhood.
The Republican...